Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference

Rhea-AI Summary

Abeona Therapeutics (NASDAQ: ABEO) announced that CEO Vish Seshadri and CCO Madhav Vasanthavada will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference. The presentation is scheduled for June 4, 2025, at 11:40 a.m. Eastern Time. Investors can access the live webcast through the company's investor relations website, and a replay will be available for 30 days following the event.

CLEVELAND, May 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Ph.D., Chief Executive Officer, and Madhav Vasanthavada, Ph.D., Chief Commercial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 11:40 a.m. Eastern Time.

A live webcast of the fireside chat can be accessed on the Investors section of the Abeona website under "Events" at https://investors.abeonatherapeutics.com/events. The webcast will be archived for 30 days.

About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN™ (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.

ZEVASKYN™, Abeona Assist™, Abeona Therapeutics^®, and their related logos are trademarks of Abeona Therapeutics Inc.

Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to commercialize ZEVASKYN, the therapeutic potential of ZEVASKYN, whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company’s expectations, continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections from the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.

Investor and Media Contact:
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
ir@abeonatherapeutics.com

FAQ

When is Abeona Therapeutics (ABEO) presenting at the Jefferies Global Healthcare Conference 2025?

Abeona Therapeutics will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 11:40 a.m. Eastern Time.

Who will represent Abeona Therapeutics (ABEO) at the Jefferies Healthcare Conference?

CEO Vish Seshadri, Ph.D., and Chief Commercial Officer Madhav Vasanthavada, Ph.D., will represent Abeona Therapeutics at the conference.

How can investors watch Abeona Therapeutics' (ABEO) presentation at the Jefferies conference?

Investors can watch the live webcast through the Investors section of Abeona's website under Events at investors.abeonatherapeutics.com/events.

How long will Abeona Therapeutics' (ABEO) Jefferies conference presentation be available for replay?

The webcast will be archived and available for replay for 30 days after the presentation.